Theriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech Grant
ROCKVILLE, Md., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced selection as …